Compare JPMorgan Chase & Co (JPM) vs McKesson Corporation (MCK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Chase & Co vs McKesson Corporation — how do they compare? JPMorgan Chase & Co trades at $332.31 (market cap $880.98B), while McKesson Corporation trades at $930 (market cap $108.46B). The key difference: JPMorgan Chase & Co is far larger — about 8.1× McKesson Corporation's market cap, and JPMorgan Chase & Co pays the higher dividend (1.99%). Which is the better fit depends on your goals — on Pluang, investors hold JPMorgan Chase & Co for 127 Days and McKesson Corporation for 74 Days on average.
| JPM | MCK | |
|---|---|---|
Market Cap | $880.98B | $108.46B |
Volume | 7,721,661 | 712,607 |
Sector | Financials | Health |
52-Week High | $365.18 | $995.69 |
52-Week Low | $282.84 | $725.17 |
Typical Hold Time | 127 Days | 74 Days |
Enterprise Value | $1.82T | $115.00B |
Dividend Yield | 1.99% | 0.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JPMorgan Chase (JPM) trades at $329.58, down 0.51% on the day, with a bearish technical signal. The stock shows strong fundamentals, with a P/E of 14.12 and net income margin of 33.38%. Recent earnings beat expectations in Q1 and Q2 2026, though Q4 2025 was a miss. Analyst consensus is a Moderate Buy with a $373.18 price target, implying potential upside. Cash flow trends show significant financing activities offsetting negative operating cash flows.
The outlook for JPM is positive based on robust profitability and analyst support, but risks include volatile cash flows, geopolitical tensions affecting banking sectors, and CEO warnings on economic challenges. The stock's current price near support at $327 suggests a potential entry point for long-term investors, though near-term bearish technicals warrant caution.
McKesson Corporation (MCK) trades at $910.33, down 1.23% today, but maintains strong analyst support with 80.65% buy ratings and a $956.43 consensus price target. The stock shows bullish technical momentum with recent earnings beats and a major distribution agreement extension with CVS Health through 2032. Revenue growth has accelerated from $264B in 2022 to $359B in 2025, though net margins remain thin at 1.12%.
MCK presents a compelling growth story with consistent earnings outperformance and strategic partnerships driving long-term visibility. However, investors face risks from margin compression, drug pricing pressures, and high leverage with negative shareholder equity. The current valuation at 24.42x P/E appears reasonable given the company's market leadership and oncology growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JPMorgan Chase & Co
JPMorgan Chase & Co. provides global financial services and retail banking. The Company provides services such as investment banking, treasury and securities services, asset management, private banking, card member services, commercial banking, and home finance. JP Morgan Chase serves business enterprises, institutions, and individuals.
Read more on JPM →About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →
